|
1）Chapkin SR, et al. Hormon-fuel interrelationships: fed state， starvation， and diabetes mellitus. In: Kahn CR, Weir GC, editors. Joslinʼs Diabetes Mellitus. 13th edition. Philadelphia: Lea＆Febiger; 1994. p. 97-115
|
|
|
|
|
2）Radziuk J, et al. Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis. Diabetes Metab Res Rev. 2001; 17: 250-72
|
|
|
|
|
3）Jitrapakdee S, et al. Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. Int J Biochem Cell Biol. 2012; 44: 33-45
|
|
|
|
|
|
4）Zhou XY, et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat Med. 2004; 10: 633-7
|
|
|
|
|
|
5）Koo SH, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005; 437: 1109-11
|
|
|
|
|
|
6）Herzig S, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001; 413: 179-83
|
|
|
|
|
|
7）Yoon JC, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001; 413: 131-8
|
|
|
|
|
|
8）Matsumoto M, et al. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007; 6: 208-16
|
|
|
|
|
|
9）Altomonte J, et al. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab. 2003; 285: E718-28
|
|
|
|
|
|
10）Accili D, et al. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004; 117: 421-6
|
|
|
|
|
|
11）Daitoku H, et al. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta. 2011; 1813: 1954-60
|
|
|
|
|
|
12）Ozcan L, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab. 2012; 15: 739-51
|
|
|
|
|
|
13）Erion DM, et al. Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab. 2009; 10: 499-506
|
|
|
|
|
|
14）Zhou XY, et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat Med. 2004; 10: 633-7
|
|
|
|
|
|
15）He L, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137: 635-46
|
|
|
|
|
|
16）He L, et al. Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis. J Biol Chem. 2012; 287: 32069-77
|
|
|
|
|
|
17）Altarejos JY, et al. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011; 12: 141-51
|
|
|
|
|
|
18）Shaw RJ, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310: 1642-6
|
|
|
|
|
|
19）Puigserver P, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1alpha interaction. Nature. 2003; 423: 550-5
|
|
|
|
|
|
20）Takashima M, et al. Role of KLF15 in regulation of hepatic gluconeogenesis and metforminaction. Diabetes. 2010; 59: 1608-15
|
|
|
|
|
|
21）Rodgers JT, et al. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 2008; 582: 46-53
|
|
|
|
|
|
22）Sakai M, et al. CITED2 links hormonal signaling to PGC-1α acetylation in regulation of gluconeogenesis. Nat Med. 2012; 18: 612-7
|
|
|
|
|
|
23）Obici S, et al. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002; 8: 1376-82
|
|
|
|
|
|
24）Pocai A, et al. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005; 1: 53-61
|
|
|
|
|
|
25）Inoue H, et al. Role of hepatic STAT3 in brain－insulin action on hepatic glucose production. Cell Metab. 2006; 3: 267-75
|
|
|
|
|
|
26）Inoue H, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med. 2004; 10: 168-74
|
|
|
|
|
|
27）Bagger JI, et al. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011; 13: 965-71
|
|
|
|
|
|
28）Miller RA, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013; 494: 256-60
|
|
|
|
|
|
29）Kadowaki T, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116: 1784-92
|
|
|
|
|
|
30）Yamauchi T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13: 332-9
|
|
|
|
|
|
31）Yamauchi T, Kadowaki T, et al. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013; 17: 185-96
|
|
|
|
|
|
32）Awazawa M, et al. Adiponectin Enhances Insulin Sensitivity by Increasing Hepatic IRS-2 Expression via a Macrophage-Derived IL-6-Dependent Pathway. Cell Metab. 2011; 13: 401-12
|
|
|
|
|